Gilead Sciences Inc.

United States of America Country flag United States of America
Sector: Biotechnology
Ticker: GILD
Factsheet Factsheet

Market multiple valuation of Gilead Sciences Inc. ( GILD | USA)

The most common multiple used in the valuation of stocks is the P/Earnings NTM multiple (Price to Earnings). P/E relates the current share price with the market expectations in terms of Earnings Per Share. This multiple is used to compare a company's market value with its earnings. A company with a high P/Earnings NTM is considered to be overvalued; a company with a low P/Earnings NTM is considered to be undervalued.
The P/Earnings NTM ratio of Gilead Sciences Inc. is significantly lower than the median of its peer group: around 12.00. The company valuation of Gilead Sciences Inc. according to these metrics is way below the market valuation of its peer group.
The P/Earnings NTM ratio of Gilead Sciences Inc. is significantly lower than the average of its sector (Biotechnology): -5.62. The company valuation of Gilead Sciences Inc. according to these metrics is way below the market valuation of its sector.
The P/Earnings NTM ratio of Gilead Sciences Inc. is slightly lower than its historical 5-year average: 9.6. The (current) company valuation of Gilead Sciences Inc. is therefore consistent with its valuation average over the last five years.

Valuation
P/E Last P/E (e) 2021P/E NTM
Gilead Sciences Inc.Free trialFree trialFree trial
International PeersFree trialFree trialFree trial
Biotechnology-7.44-5.77-5.62
NASDAQ 10037.8426.6426.81
United States of America-2.0213.6714.06
More...
Beta (Ref: NASDAQ 100)
Levered betaUnlevered beta
1-Year0.280.28
2-Year0.270.27
3-Year0.410.40
More...
Stock Perf excl. Dividends (in USD)
GILDNASDAQ 100Rel. Perf.
Year-to-Date14.8%9.0%5.8%
1-Week2.7%1.4%1.3%
1-Month4.5%6.8%-2.3%
1-Year-12.6%60.3%-73.0%
3-Year-10.5%110.4%-120.8%
5-Year-32.0%209.1%-241.0%
More...
International Peers - Gilead Sciences Inc.
Company NameCtryMarket
Cap.
last (mUSD)
Gilead Sciences Inc.USA84 029
International Peers Median0.52
United Therapeutics Cor...USA9 075
Bristol-Myers Squibb Co...USA146 233
Pfizer Inc.USA215 150
GlaxoSmithKline plcGBR93 383
Merck & Co., Inc.USA196 024
GPRV Analysis
Gilead Sciences Inc.
Intl. Peers
U.S Patents No. 7,882,001 & 8,082,201
More...
Net Sales Chart
More...
Quotes Chart

1-Year Rebased Stock Chart

  • Gilead Sciences Inc.
  • NASDAQ 100
More...

Did you know ?

On the Infront Analytics platform, there are two ways to identify the listed peers which most closely resemble a private firm:
- with Peer Tracker if you already know a listed peer.
Peer Tracker is a patented technology tool for building peer groups using industry classifications. The degree of similarity between two companies is calculated comparing their sector footprints and measured using comparability scores.
- with Market Screener if you have no listed peer in mind.
Market Screener is a dedicated interface for screening companies using multiple criteria, identifying peers, searching for comparable companies in a specific business sector.

About Market Multiples

Many methods can be used to value a company. In reality, business valuation is often a combination of these different approaches. One of the most widely used quantitative methods is the market multiples method. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business.
Current multiples include:
- Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM);
- Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1.
Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).